1don MSN
Reducing inflammation may protect against early age-related macular degeneration-like vision loss
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics ...
Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...
News-Medical.Net on MSN
Inflammation control can protect against AMD-like retinal damage
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...
Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for ...
GlobalData on MSN
Regeneron’s Eylea franchise boosted by pair of FDA approvals
Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly ...
Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal ...
Regeneron (REGN) announced that the FDA has approved Eylea HD Injection 8 mg for the treatment of patients with macular edema following retinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback